Table 3 Correlation of clinical data with measures in EVs from clinical cohort 2 (cohort from Lille University Hospital).

From: Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers

		WEIGHT	HEIGHT	BMI	AGE at Sampling	AGE at ONSET	AGE at DIAG	DIAG DURATION	de novo	LEDD	UPDRS III	H&Y	Schwab & England	MMS	MoCA	DEMENTIA
Total LRRK2	Pearson’s r	0.267	0.1763	0.1942	0.06265	−0.08305	−0.08339	0.08399	−0.1826	0.07935	0.2749	0.1295	−0.04577	−0.06448	−0.05424	−0.048
	P (two-tailed)	0.0043	0.0629	0.0402	0.5098	0.5281	0.5264	0.5234	0.1626	0.5468	0.1215	0.3241	0.7284	0.4975	0.6806	0.7433
	P-value summary	**	ns	*	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Rab8	Pearson’s r	0.1884	0.05904	0.1974	−0.09921	−0.1681	−0.1725	0.1346	−0.1862	0.17	0.1265	−0.08077	−0.07776	0.01325	0.03446	0.08787
	P (two-tailed)	0.0457	0.5363	0.037	0.2958	0.1993	0.1875	0.3051	0.1543	0.1941	0.4831	0.5396	0.5548	0.8892	0.7938	0.5482
	P-value summary	*	ns	*	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
TSG101	Pearson’s r	0.2167	0.1109	0.1927	−0.1093	−0.1546	−0.1552	0.1067	−0.1573	0.1965	0.1662	−0.0634	−0.09658	0.02681	0.003682	0.0833
	P (two-tailed)	0.0212	0.2444	0.0418	0.249	0.2382	0.2364	0.4173	0.23	0.1323	0.3552	0.6303	0.4629	0.778	0.9777	0.5693
	P-value summary	*	ns	*	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
pT72-Rab8	Pearson’s r	−0.01749	−0.02261	−0.02519	0.05429	0.3094	0.2963	−0.181	−0.05387	0.05604	0.06888	0.129	−0.1306	−0.1074	0.1131	0.1226
	P (two-tailed)	0.8621	0.8233	0.8035	0.5897	0.0228	0.0296	0.1903	0.6989	0.6873	0.7226	0.3527	0.3464	0.2851	0.4156	0.4277
	P-value summary	ns	ns	ns	ns	*	*	ns	ns	ns	ns	ns	ns	ns	ns	ns
pS910-LRRK2	Pearson’s r	0.1914	0.1253	0.07958	-0.07421	-0.4123	-0.4261	-0.2204	0.2038	-0.3836	-0.5919	-0.2628	0.1582	0.1351	0.408	−0.3649
	P (two-tailed)	0.1537	0.3574	0.5599	0.5832	0.0794	0.0689	0.3646	0.4027	0.1049	0.1222	0.277	0.5178	0.3162	0.0829	0.1499
	P-value summary	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
pS935-LRRK2	Pearson’s r	0.007961	−0.02278	0.04586	0.04341	−0.01878	−0.03096	0.1223	−0.1131	0.1884	0.08682	−0.05449	−0.1752	0.1656	0.1049	−0.003233
	P (two-tailed)	0.9364	0.8202	0.6472	0.6633	0.8918	0.8225	0.3739	0.411	0.1684	0.6605	0.6927	0.2007	0.0945	0.3911	0.983
	P-value summary	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
pS1292-LRRK2	Pearson’s r	−0.01756	−0.1706	0.1271	0.1708	0.1754	0.1435	0.06422	−0.3625	0.002997	0.2859	−0.1077	0.1275	0.09997	0.03103	0.03205
	P (two-tailed)	0.9037	0.2412	0.3842	0.2356	0.3914	0.4845	0.7553	0.0688	0.9884	0.4232	0.6005	0.5347	0.4897	0.8804	0.8846
	P value summary	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns

LEDD L-dopa equivalent daily dosage, MMSE Mini-Mental State Examination, MoCA The Montreal Cognitive Assessment, UPDRS Unified Parkinson’s Disease Rating Scale. *P < 0,05; ns not significant.

Back to article page

Table 3 Correlation of clinical data with measures in EVs from clinical cohort 2 (cohort from Lille University Hospital).

Search

Quick links